One of the industry’s leading small-molecule CDMOs is being acquired for $2.4 billion.
New Jersey-based Cambrex Corporation announced this week that it is being acquired by an affiliate of the private equity firm Permina Funds.
Cambrex completed two major acquisitions of its own in the last year including a $252 million purchase of Avista Pharma Solutions and a $425 million buyout of another CDMO, Halo Pharma. According to Cambrex, the acquisitions allowed the company to add product manufacturing and analytical testing services to its drug substance manufacturing capabilities, creating a full portfolio of product life-cycle services.
Cambrex says the recent acquisition by Permina is an endorsement of its strategy and “represents significant value for our shareholders.
Read the press release.
